A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Drug Discovery and Structural Biology (DDSB) Core Bookmark and Share

Drug Discovery and Structural Biology (DDSB) Core

A primary goal of City of Hope's Comprehensive Cancer Center and its research programs is to develop new, more effective and less toxic therapies for the treatment of cancer. The Drug Discovery and Structural Biology (DDSB) Core was established to provide the necessary technical and scientific resource to facilitate drug discovery efforts consistent with the cancer center’s translational research goals. An important focus of the DDSB is on cancer drug discovery in the area of molecular-targeted therapeutics, as well as chemical biology probes. The core was established with these goals in mind and therefore is highly diverse in its services, yet highly convergent in its efforts.  The core comprises four major service components: high throughput screening, biopolymer synthesis, small molecule synthesis and X-ray crystallography. These disciplines work together in a complementary and cohesive manner to provide a full array of early-phase drug discovery services and chemical probes for biological systems. 
 
For example, the high throughput screening component of the DDSB provides unique opportunities for discovering small-molecule inhibitors of targeted proteins. Next, lead compounds can be elaborated through medicinal chemistry and structure activity relationship studies.  Once a good lead compound is developed, X-ray crystallographic analysis of the drug-protein complex begins. This is an essential component of any drug development process, since a detailed structural analysis is critical to understanding the drug-protein interaction and facilitates the optimization of ligand binding by molecular design. The general capabilities of the DDSB are significant and include the design and synthesis of highly specialized biopolymers, including siRNA-aptamers, DNA-peptide hybrid derivatives and peptides >100 amino acids in length.  In addition, the core maintains expertise in synthetic organic chemistry and is capable of complex molecule synthesis as well as the synthesis of small-molecule agonists and antagonists, imaging agents, affinity ligands, nanoparticles and focused combinatorial libraries. These compounds are used for mechanistic studies in chemical biology, generation of lead compounds for drug discovery, drug optimization for preclinical evaluation and, ultimately, development of new-targeted cancer therapeutics. 
 
The DDSB is capable of synthesizing all structural classes from small to large organic molecules including air- and light-sensitive materials. The synthetic component of the DDSB works closely with the new Chemical GMP Synthesis Facilities in developing good manufacturing practice synthesis processes for investigational new drug submissions. The other significant aspect of the DDSB lies in the structural characterization of drug-protein complexes by X-ray crystallography and other biophysical techniques such as surface plasmon resonance, isothermal titration calorimetry, and analytical ultracentrifugation. This unique transdisciplinary core enables development of new molecularly-targeted compounds for chemical biology studies and cancer therapies to enhance our translational research mission of the City of Hope Comprehensive Cancer Center. The goal of developing targeted molecular cancer therapeutics within various research programs of the cancer center is greatly facilitated through the newly-expanded, integrated DDSB facility.
 
Any subcomponent of the DDSB can be utilized on a stand-alone basis for a specific application.  Please contact the co-directors or managers at the links below for more information on usage, pricing and availability.
 
David Horne, Ph.D.
Co-director
626-256-4673, ext. 67310
dhorne@coh.org
 
John C. Williams, Ph.D.
Co-director
626-256-HOPE (4673), ext. 60227
jwilliams@coh.org

Drug Discovery and Structural Biology (DDSB) Core

Drug Discovery and Structural Biology (DDSB) Core

A primary goal of City of Hope's Comprehensive Cancer Center and its research programs is to develop new, more effective and less toxic therapies for the treatment of cancer. The Drug Discovery and Structural Biology (DDSB) Core was established to provide the necessary technical and scientific resource to facilitate drug discovery efforts consistent with the cancer center’s translational research goals. An important focus of the DDSB is on cancer drug discovery in the area of molecular-targeted therapeutics, as well as chemical biology probes. The core was established with these goals in mind and therefore is highly diverse in its services, yet highly convergent in its efforts.  The core comprises four major service components: high throughput screening, biopolymer synthesis, small molecule synthesis and X-ray crystallography. These disciplines work together in a complementary and cohesive manner to provide a full array of early-phase drug discovery services and chemical probes for biological systems. 
 
For example, the high throughput screening component of the DDSB provides unique opportunities for discovering small-molecule inhibitors of targeted proteins. Next, lead compounds can be elaborated through medicinal chemistry and structure activity relationship studies.  Once a good lead compound is developed, X-ray crystallographic analysis of the drug-protein complex begins. This is an essential component of any drug development process, since a detailed structural analysis is critical to understanding the drug-protein interaction and facilitates the optimization of ligand binding by molecular design. The general capabilities of the DDSB are significant and include the design and synthesis of highly specialized biopolymers, including siRNA-aptamers, DNA-peptide hybrid derivatives and peptides >100 amino acids in length.  In addition, the core maintains expertise in synthetic organic chemistry and is capable of complex molecule synthesis as well as the synthesis of small-molecule agonists and antagonists, imaging agents, affinity ligands, nanoparticles and focused combinatorial libraries. These compounds are used for mechanistic studies in chemical biology, generation of lead compounds for drug discovery, drug optimization for preclinical evaluation and, ultimately, development of new-targeted cancer therapeutics. 
 
The DDSB is capable of synthesizing all structural classes from small to large organic molecules including air- and light-sensitive materials. The synthetic component of the DDSB works closely with the new Chemical GMP Synthesis Facilities in developing good manufacturing practice synthesis processes for investigational new drug submissions. The other significant aspect of the DDSB lies in the structural characterization of drug-protein complexes by X-ray crystallography and other biophysical techniques such as surface plasmon resonance, isothermal titration calorimetry, and analytical ultracentrifugation. This unique transdisciplinary core enables development of new molecularly-targeted compounds for chemical biology studies and cancer therapies to enhance our translational research mission of the City of Hope Comprehensive Cancer Center. The goal of developing targeted molecular cancer therapeutics within various research programs of the cancer center is greatly facilitated through the newly-expanded, integrated DDSB facility.
 
Any subcomponent of the DDSB can be utilized on a stand-alone basis for a specific application.  Please contact the co-directors or managers at the links below for more information on usage, pricing and availability.
 
David Horne, Ph.D.
Co-director
626-256-4673, ext. 67310
dhorne@coh.org
 
John C. Williams, Ph.D.
Co-director
626-256-HOPE (4673), ext. 60227
jwilliams@coh.org
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media
 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 


NEWS & UPDATES
  • Patients undergoing treatment at City of Hope know they will be receiving the best medical care available, that their treatment will be delivered with compassion and that their care will extend to their families. “When we treat a patient here, we treat a family,” says Jo Ann S. Namm, child life manager and spec...
  • Did you know that colorectal cancer equally affects men and women? Or that it’s the third-leading cause of cancer death in the U.S.? Most important, did you know that colorectal cancer is very treatable and highly curable if detected early? If you didn’t know these facts, it’s time to learn. M...
  • To celebrate the beginning of Lunar New  Year 2015, City of Hope honored not just a new lunar calendar, but also the diversity of the community it serves. On Jan. 21, as tens of thousands of people celebrated Lunar New Year (and the arrival of the Year of the Ram) in the streets of L.A.’s Chinatown, City of [&#...
  • The breakthroughs that have revolutionized cancer treatment, transforming cancer in many cases to a very manageable and even curable disease, started out as just ideas. “I will often tell patients there’s no therapy we’re using to help them that wasn’t derived from somebody’s idea in some laboratory, working la...
  • The prostate cancer screening debate, at least as it relates to regular assessment of prostate specific antigen levels, is far from over. The U.S. Preventive Services Task Force recommended against routine PSA screening for prostate cancer in 2012, maintaining that the routine use of the PSA blood test does mor...
  • Cancer patients should get more than medical treatment. They should get comprehensive, evidence-based care that addresses their full range of needs. That kind of patient-focused care is City of Hope’s specialty. Under the guidance of Dawn Gross, M.D., Ph.D., the new Arthur M. Coppola Family Chair in Suppo...
  • Think twice before tossing out those hormone replacement pills. Although a new Lancet study suggests that hormone replacement therapy could increase a woman’s risk of ovarian cancer, a City of Hope expert urges women to keep this news in perspective. Hormone replacement therapy is prescribed to help allev...
  • Don’t know what to take, or send, that friend of yours in the hospital? Try a paper plate — filled not with cookies or sweets, but an image of yourself. Ilana Massi, currently undergoing treatment at City of Hope for acute myeloid leukemia, can vouch for the power of such a gift. She’s surrounded herself [̷...
  • With precision medicine now a national priority, City of Hope has joined a novel research partnership designed to further understanding of cancer at the molecular level, ultimately leading to more targeted cancer treatments. The Oncology Research Information Exchange Network, or ORIEN, is the world’s larg...
  • The spinal cord is an integral part of the human body, connecting the brain to everything else. So when a tumor grows on the spine, any messages that the brain tries to send to the rest of the body are interrupted, making everyday tasks — such as walking — more difficult. This year an estimated 22,850 […]
  • Each year, thousands of patients with hematologic malignancies undergo allogeneic stem cell transplantation (that is, they receive a donor’s stem cells), offering them a chance at cure. Graft-versus-host disease is a potentially deadly complication of this therapy and occurs in approximately 25 to 60 perc...
  • Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, offers his perspective on the benefits of surgery for aggressive prostate cancer. For men walking out of the doctor’s office after a diagnosis of cancer, the reality can hit like a ton of bricks. Th...
  • Although many Hispanic women face a high risk of mutations in the BRCA1 and BRCA2 genes – increasing their risk of breast and ovarian cancer – screenings for these mutations can be prohibitively expensive in Mexico and other Latin American countries. As a result, too many women don’t get the information t...
  • Providing lung cancer treatments to patients when their cancer is at its earliest and most treatable stages will now be a more attainable goal: Medicare has agreed to cover lung cancer screening for those beneficiaries who meet the requirements. The only proven way to detect lung cancer early enough to save liv...
  • At City of Hope, innovative scientific research, important clinical studies and vital construction projects are all powered by philanthropy. Generous supporters fuel a powerful and diverse range of progress in science and medicine, enabling researchers and clinicians to improve cancer treatments and create cure...